RLAY · Coteau

RLAY

$17.09

+4.98% 2026-10-19

Sector n/a

1M 3M 6M 1Y 2Y

RLAYSPY

-4.9%

-9.3%

-10.9%

+4.2%

YTD

+102.0%

+163.3%

Grades vs sector

Momentum

no data

–

Percentile within its GICS sector across the S&P 1500.

Growth

no data

–

Percentile within its GICS sector across the S&P 1500.

Value

no data

–

Percentile within its GICS sector across the S&P 1500.

Profitability

no data

–

Percentile within its GICS sector across the S&P 1500.

Revisions

no data

–

30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 3 live models right now.

Momentum Top 15

not ranked (outside this model's universe or screens)

Quality Growth

not ranked (outside this model's universe or screens)

Momentum Blend

not in the current book

Key stats

Market cap–

P/E (trailing)–

P/E (forward)–

52-week range– – –

Revenue growth (YoY, latest qtr)–

Dividend yield–

Analyst consensus–

Mean price target–

Valuation & fundamentals

Bottom line

No cash-flow valuation

Model read-out from the numbers below, not advice. Score +0 (DCF counts double).

•Piotroski F-score4/9

Discounted cash flow

Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.

Reverse DCFfor context, not a signal

Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs sector

Quality & financial health

Gross margin

–

Operating margin

-2999.4%

FCF margin

-2050.3%

Net margin

-2763.6%

Return on equity

-32.1%

Return on invested capital

-31.9%

Net debt / EBITDA

–

Current ratio

18.3×

Interest cover

–

Cash conversion (OCF/NI)

–

Piotroski F-score 4/9 · last two fiscal years

✗ Positive net income✗ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved

Analysts

No analyst targets available.

Annual history

FY	Revenue	Net income	Free cash flow
2025	$15.4M	$-276.5M	$-235.9M
2024	$10.0M	$-337.7M	$-251.1M
2023	$25.5M	$-342.0M	$-304.4M
2022	$1.4M	$-290.5M	$-238.6M
2021	$3.0M	$-363.9M	$-77.9M
2020	$82.7M	$-52.4M	$-104.4M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +123.2%.

Earnings

Next report: 2026-11-05 · during market · EPS est -0.40

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-08-06	-0.39	-0.41	-4.4%
2026-05-05	-0.36	-0.41	-15.0%
2026-02-26	-0.40	-0.31	+21.7%
2025-11-06	-0.42	-0.43	-2.8%
2025-08-07	-0.47	-0.41	+13.0%
2025-05-05	-0.48	-0.46	+4.1%
2025-02-26	-0.55	-0.45	+17.9%
2024-11-06	-0.78	-0.63	+19.6%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$350.0K	-48.3%
2026-03-31	$3.0M	–
2025-12-31	$7.0M	–
2025-09-30	$0	–
2025-06-30	$677.0K	–

Analyst actions

HC Wainwright & Co.

2026-08-20 · main

Buy → Buy
PT $29

JP Morgan

2026-08-14 · main

Overweight → Overweight
PT $31

Citizens

2026-08-10 · main

Market Outperform → Market Outperform
PT $26

Barclays

2026-08-07 · main

Overweight → Overweight
PT $30

Goldman Sachs

2026-07-21 · main

Buy → Buy
PT $31

Canaccord Genuity

2026-07-16 · init

→ Buy
PT $29

Insider trades

Patel Sanjiv

Director, President and CEO · 2026-10-07

SELL
$872.4K

Catinazzo Thomas

Chief Financial Officer · 2026-10-06

SELL
$325.4K

Catinazzo Thomas

Chief Financial Officer · 2026-10-06

SELL
$4.0K

Bergstrom Donald A

President, R&D · 2026-09-08

SELL
$161.8K

Catinazzo Thomas

Chief Financial Officer · 2026-09-08

SELL
$335.6K

Patel Sanjiv

Director, President and CEO · 2026-09-08

SELL
$912.9K

Rahmer Peter

See remarks · 2026-08-26

SELL
$90.3K

Svf Pauling (Cayman) Ltd

10% owner · 2026-08-25

SELL
$116.4M

Patel Sanjiv

Director, President and CEO · 2026-08-17

SELL
$979.9K

Catinazzo Thomas

Chief Financial Officer · 2026-08-14

SELL
$349.7K

Catinazzo Thomas

Chief Financial Officer · 2026-07-28

SELL
$27.2K

Rahmer Peter

See remarks · 2026-07-28

SELL
$13.9K

News

What Could Go Wrong With Recursion Pharmaceuticals Stock?

Trefis · Oct 08

Relay Therapeutics Insider Sold Shares Worth $872,402, According to a Recent SEC Filing

MT Newswires · Oct 08

Relay Therapeutics Insider Sold Shares Worth $329,322, According to a Recent SEC Filing

MT Newswires · Oct 08

Relay Therapeutics (RLAY) Stock Looks Fully Priced On Book Value

Simply Wall St. · Oct 08

Is Relay Therapeutics (RLAY) Cheap After Its Pullback Or Is The Upside Priced In?

Simply Wall St. · Oct 07

Raymond James Updates Healthcare Top Picks for October

Investing.com · Oct 01

Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?

Zacks · Sep 24

X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics

GlobeNewswire · Sep 22

Stats refreshed 2026-10-19 19:03:10 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

coteau

Coteau Systematic StrategiesSystematic equity research and model portfolios.
Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.

What is Coteau?Disclaimer Terms Privacy Data status